
PolyPeptide Group Investor Relations Material
Latest events

H2 2024
PolyPeptide Group
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from PolyPeptide Group AG
Access all reports
PolyPeptide Group AG is a leading contract development and manufacturing organization (CDMO) specializing in the production of peptides and related molecules. The company provides services across the entire development spectrum, from initial peptide synthesis to commercial-scale manufacturing. PolyPeptide supports pharmaceutical and biotech companies with both proprietary and generic Good Manufacturing Practice (GMP)-grade peptides used in approved pharmaceutical products, drugs in clinical development, and in generic products. Additionally, it manufactures a variety of peptides used in cosmetic applications. The company is headquartered in Baar, Canton of Zug, Switzerland, and its shares are listed on the stock exchange.
Key slides for PolyPeptide Group AG


H2 2024
PolyPeptide Group AG


H2 2024
PolyPeptide Group AG
Latest articles
)
The Rise and Fall of Wirecard
A look inside the Wirecard scandal, which took the company from the prestigious DAX 30 to insolvency through the largest accounting fraud in European history.
16 May 2025
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
Ticker symbol
PPGN
Country
🇨🇭 Switzerland